Search

Your search keyword '"Edan, G."' showing total 763 results
Start Over Author "Edan, G."
763 results on '"Edan, G."'

6. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Author

Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand’Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T., and Leray, E.

Published
2022
Full Text
View/download PDF

7. Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI

Author

Brochet, B., Casey, R., Cotton, F., De Sèze, J., Douek, P., Guillemin, F., Laplaud, D., Lebrun-Frenay, C., Mansuy, L., Moreau, T., Olaiz, J., Pelletier, J., Rigaud-Bully, C., Stankoff, B., Vukusic, S., Marignier, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., Collongues, N., Lubetzki, C., Vermersch, P., Labauge, P., Defer, G., Cohen, M., Fromont, A., Wiertlewsky, S., Berger, E., Clavelou, P., Audoin, B., Giannesini, C., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Créange, A., Camdessanché, J.-P., Faure, J., Maurousset, A., Patry, I., Hankiewicz, K., Pottier, C., Maubeuge, N., Labeyrie, C., Nifle, C., Ameli, R., Anxionnat, R., Attye, A., Bannier, E., Barillot, C., Ben Salem, D., Boncoeur-Martel, M.-P., Bonneville, F., Boutet, C., Brisset, J.-C., Cervenanski, F., Claise, B., Commowick, O., Constans, J.-M., Dardel, P., Desal, H., Dousset, Vincent, Durand-Dubief, F., Ferre, J.-C., Gerardin, E., Glattard, T., Grand, S., Grenier, T., Guillevin, R., Guttmann, C., Krainik, A., Kremer, S., Lion, S., Menjot de Champfleur, N., Mondot, L., Outteryck, O., Pyatigorskaya, N., Pruvo, J.-P., Rabaste, S., Ranjeva, J.-P., Roch, J.-A., Sadik, J.C., Sappey-Marinier, D., Savatovsky, J., Tanguy, J.-Y., Tourbah, A., Tourdias, T., Roca, P., Colas, L., Tucholka, A., Rubini, P., Cackowski, S., Ding, J., Budzik, J.-F., Renard, F., Doyle, S., Barbier, E.L., Bousaid, I., Lassau, N., and Verclytte, S.

Published
2020
Full Text
View/download PDF

8. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions

Author

Ameli, R., Anxionnat, R., Audoin, B., Attye, A., Bannier, E., Barillot, C., Ben Salem, D., Boncoeur-Martel, M.-P., Bonhomme, G., Bonneville, F., Boutet, C., Brisset, J.C., Cervenanski, F., Claise, B., Commowick, O., Constans, J.-M., Cotton, F., Dardel, P., Desal, H., Dousset, V., Durand-Dubief, F., Ferre, J.-C., Gaultier, A., Gerardin, E., Glattard, T., Grand, S., Grenier, T., Guillevin, R., Guttmann, C., Krainik, A., Kremer, S., Lion, S., Champfleur, N. Menjot De, Mondot, L., Outteryck, O., Pyatigorskaya, N., Pruvo, J.-P., Rabaste, S., Ranjeva, J.-P., Roch, J.-A., Sadik, J.-C., Sappey-Marinier, D., Savatovsky, J., Stankoff, B., Tanguy, J.-Y., Tourbah, A., Tourdias, T., Brochet, B., Casey, R., De Sèze, J., Douek, P., Guillemin, F., Laplaud, D., Lebrun-Frenay, C., Mansuy, L., Moreau, T., Olaiz, J., Pelletier, J., Rigaud-Bully, C., Vukusic, S., Debouverie, M., Edan, G., Ciron, J., Lubetzki, C., Vermersch, P., Labauge, P., Defer, G., Berger, E., Clavelou, P., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Créange, A., Camdessanché, J.-P., Bakchine, S., Maurousset, A., Patry, I., De Broucker, T., Pottier, C., Neau, J.-P., Labeyrie, C., Nifle, C., Brisset, Jean-Christophe, Kremer, Stephane, Hannoun, Salem, Bonneville, Fabrice, Durand-Dubief, Francoise, Tourdias, Thomas, Barillot, Christian, Guttmann, Charles, Vukusic, Sandra, Dousset, Vincent, and Cotton, Francois

Published
2020
Full Text
View/download PDF

11. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Author

Abadie, V., Achour, C., Ader, F., Alchaar, H., Alkhedr, A., Andreux, F., Androdias, G., Arjmand, R., Audoin, B., Audry, D., Aufauvre, D., Autreaux, C., Ayrignac, X., Bailbe, M., Benazet, M., Bensa, C., Bensmail, D., Berger, E., Bernady, P., Bertagna, Y., Biotti, D., Blanchard-Dauphin, A., Bonenfant, J., Bonnan, M., Bonnemain, B., Borgel, F., Botelho-Nevers, E., Boucly, S., Bourre, B., Boutière, C., Branger, P., Brassat, D., Bresch, S., Breuil, V., Brochet, B., Brugeilles, H., Bugnon, P., Cabre, P., Camdessanché, J.-P., Carra-Dalière, C., Casez, O., Chamouard, J.-M., Chassande, B., Chataignier, P., Chbicheb, M., Chenet, A., Ciron, J., Clavelou, P., Cohen, M., Colamarino, R., Collongues, N., Coman, I., Corail, P.-R., Courtois, S., Coustans, M., Creange, A., Creisson, E., Daluzeau, N., Davenas, C., De Seze, J., Debouverie, M., Depaz, R., Derache, N., Divio, L., Douay, X., Dulau, C., Durand-Dubief, F., Edan, G., Elias, Z., Fagniez, O., Faucher, M., Faucheux, J.-M., Fournier, M., Gagneux-Brunon, A., Gaida, P., Galli, P., Gallien, P., Gaudelus, J., Gault, D., Gayou, A., Genevray, M., Gentil, A., Gere, J., Gignoux, L., Giroux, M., Givron, P., Gout, O., Grimaud, J., Guennoc, A.-M., Hadhoum, N., Hautecoeur, P., Heinzlef, O., Jaeger, M., Jeannin, S., Kremer, L., Kwiatkowski, A., Labauge, P., Labeyrie, C., Lachaud, S., Laffont, I., Lanctin-Garcia, C., Lannoy, J., Lanotte, L., Laplaud, D., Latombe, D., Lauxerois, M., Le Page, E., Lebrun-Frenay, C., Lejeune, P., Lejoyeux, P., Lemonnier, B., Leray, E., Loche, C.-M., Louapre, C., Lubetzki, C., Maarouf, A., Mada, B., Magy, L., Maillart, E., Manchon, E., Marignier, R., Marque, P., Mathey, G., Maurousset, A., Mekies, C., Merienne, M., Michel, L., Milor, A.-M., Moisset, X., Montcuquet, A., Moreau, T., Morel, N., Moussa, M., Naudillon, J.-P., Normand, M., Olive, P., Ouallet, J.-C., Outteryck, O., Pacault, C., Papeix, C., Patry, I., Peaureaux, D., Pelletier, J., Pichon, B., Pittion, S., Planque, E., Pouget, M.-C., Pourcher, V., Radot, C., Robert, I., Rocher, F., Ruet, A., Saint-Val, C., Salle, J.-Y., Salmon, A., Sartori, E., Schaeffer, S., Stankhof, B., Taithe, F., Thouvenot, E., Tizon, C., Tourbah, A., Tourniaire, P., Vaillant, M., Vermersch, P., Vidil, S., Wahab, A., Warter, M.-H., Wiertlewski, S., Wiplosz, B., Wittwer, B., Zaenker, C., Zephir, H., Lebrun, C., and Vukusic, S.

Published
2019
Full Text
View/download PDF

13. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients

Author

Balloy, G., Pelletier, J., Suchet, L., Lebrun, C., Cohen, M., Vermersch, P., Zephir, H., Duhin, E., Gout, O., Deschamps, R., Le Page, E., Edan, G., Labauge, P., Carra-Dallieres, C., Rumbach, L., Berger, E., Lejeune, P., Devos, P., N’Kendjuo, J.-B., Coustans, M., Auffray-Calvier, E., Daumas-Duport, B., Michel, L., Lefrere, F., Laplaud, D. A., Brosset, C., Derkinderen, P., de Seze, J., Wiertlewski, S., and On behalf of the Société Francophone de la Sclérose en Plaques

Published
2018
Full Text
View/download PDF

16. The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions

Author

Zaratin, P, Vermersch, P, Amato, M, Brichetto, G, Coetzee, T, Cutter, G, Edan, G, Giovannoni, G, Gray, E, Hartung, H, Hobart, J, Helme, A, Hyde, R, Khan, U, Leocani, L, Mantovani, L, Mcburney, R, Montalban, X, Penner, I, Uitdehaag, B, Valentine, P, Weiland, H, Bertorello, D, Battaglia, M, Baneke, P, Comi, G, Zaratin P., Vermersch P., Amato M. P., Brichetto G., Coetzee T., Cutter G., Edan G., Giovannoni G., Gray E., Hartung H. P., Hobart J., Helme A., Hyde R., Khan U., Leocani L., Mantovani L. G., McBurney R., Montalban X., Penner I. -K., Uitdehaag B. M. J., Valentine P., Weiland H., Bertorello D., Battaglia M. A., Baneke P., Comi G., Zaratin, P, Vermersch, P, Amato, M, Brichetto, G, Coetzee, T, Cutter, G, Edan, G, Giovannoni, G, Gray, E, Hartung, H, Hobart, J, Helme, A, Hyde, R, Khan, U, Leocani, L, Mantovani, L, Mcburney, R, Montalban, X, Penner, I, Uitdehaag, B, Valentine, P, Weiland, H, Bertorello, D, Battaglia, M, Baneke, P, Comi, G, Zaratin P., Vermersch P., Amato M. P., Brichetto G., Coetzee T., Cutter G., Edan G., Giovannoni G., Gray E., Hartung H. P., Hobart J., Helme A., Hyde R., Khan U., Leocani L., Mantovani L. G., McBurney R., Montalban X., Penner I. -K., Uitdehaag B. M. J., Valentine P., Weiland H., Bertorello D., Battaglia M. A., Baneke P., and Comi G.

Abstract

On 12 September 2019, the global Patient Reported Outcome for Multiple Sclerosis (PROMS) Initiative was launched at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The multi-stakeholder PROMS Initiative is jointly led by the European Charcot Foundation (ECF) and the Multiple Sclerosis International Federation (MSIF), with the Italian Multiple Sclerosis Society (AISM) acting as the lead agency for and on behalf of the global MSIF movement. The initiative has the ambitious mission to (i) maximize the impact of science with and of patient input on the life of people affected by MS, and (ii) to represent a unified view on Patient-Reported Outcomes for MS to people affected by MS, healthcare providers, regulatory agencies and Health Technologies Assessments agencies. Equipped with an innovative participatory governance of an international and interdisciplinary network of different stakeholders, PROMS has the potential to guide future breakthroughs in MS patient-focused research and care. In this paper we present the progresses of the global PROMS Initiative and discuss the open questions that we aim to address.

Published
2022

18. Mass cytometry blood immunophenotyping of RRMS patients at diagnosis helps in deciphering subtle changes in myeloid compartment associated to disease evolution

Author

Rodriguez, S., Couloume, L., Ferrant, J., Mandon, M., Jean, R., Le Gallou, S., Zéphir, H, Edan, G., Thouvenot, E., Ruet, A., Debouverie, M, Tarte, K., Amé, P., Roussel, M., Michel, Laure, Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] (CRC-SEP Nord-Pas de Calais), Service de Neurologie [Rennes] = Neurology [Rennes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), and Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience

Published
2022
Full Text
View/download PDF

19. STREM: A Robust Multidimensional Parametric Method to Segment MS Lesions in MRI

Author

Aït-Ali, L. S., Prima, S., Hellier, P., Carsin, B., Edan, G., Barillot, C., Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Duncan, James S., editor, and Gerig, Guido, editor

Published
2005
Full Text
View/download PDF

27. Signes et symptômes de la sclérose en plaques

Author

Brochet, Bruno, primary, Lebrun-Frénay, Christine, additional, de Sèze, Jérôme, additional, Zéphir, Hélène, additional, Allart, E., additional, Audoin, B., additional, Ayrignac, X., additional, Bensa, C., additional, Blanchard-Dauphin, A., additional, Brassat, D., additional, Carra-Dallière, C., additional, Clavelou, P., additional, Cohen, M., additional, Créange, A., additional, Collongues, N., additional, Debouverie, M., additional, Defer, G., additional, de Sèze, M., additional, Donzé, C., additional, Edan, G., additional, Fromont, A., additional, Gamé, X., additional, Gout, O., additional, Guillon, C., additional, Harand, C., additional, Jenny, B., additional, Labauge, P., additional, Lalive, P.-H., additional, Le Page, E., additional, Marque, P., additional, Michel, L., additional, Moisset, X., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pelé, F., additional, Pelletier, J., additional, Pittion-Vouyovitch, S., additional, Ramelli, A.-L., additional, Ruet, A., additional, Thouvenot, E., additional, Veillard, D., additional, Vignal-Clermont, C., additional, and Vukusic, S., additional

Published
2017
Full Text
View/download PDF

28. Diagnostics différentiels de la sclérose en plaques

Author

Brochet, Bruno, primary, Lebrun-Frénay, Christine, additional, de Sèze, Jérôme, additional, Zéphir, Hélène, additional, Allart, E., additional, Audoin, B., additional, Ayrignac, X., additional, Bensa, C., additional, Blanchard-Dauphin, A., additional, Brassat, D., additional, Carra-Dallière, C., additional, Clavelou, P., additional, Cohen, M., additional, Créange, A., additional, Collongues, N., additional, Debouverie, M., additional, Defer, G., additional, de Sèze, M., additional, Donzé, C., additional, Edan, G., additional, Fromont, A., additional, Gamé, X., additional, Gout, O., additional, Guillon, C., additional, Harand, C., additional, Jenny, B., additional, Labauge, P., additional, Lalive, P.-H., additional, Le Page, E., additional, Marque, P., additional, Michel, L., additional, Moisset, X., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pelé, F., additional, Pelletier, J., additional, Pittion-Vouyovitch, S., additional, Ramelli, A.-L., additional, Ruet, A., additional, Thouvenot, E., additional, Veillard, D., additional, Vignal-Clermont, C., additional, and Vukusic, S., additional

Published
2017
Full Text
View/download PDF

29. Thérapeutiques et prise en charge de la sclérose en plaques

Author

Brochet, Bruno, primary, Lebrun-Frénay, Christine, additional, de Sèze, Jérôme, additional, Zéphir, Hélène, additional, Allart, E., additional, Audoin, B., additional, Ayrignac, X., additional, Bensa, C., additional, Blanchard-Dauphin, A., additional, Brassat, D., additional, Carra-Dallière, C., additional, Clavelou, P., additional, Cohen, M., additional, Créange, A., additional, Collongues, N., additional, Debouverie, M., additional, Defer, G., additional, de Sèze, M., additional, Donzé, C., additional, Edan, G., additional, Fromont, A., additional, Gamé, X., additional, Gout, O., additional, Guillon, C., additional, Harand, C., additional, Jenny, B., additional, Labauge, P., additional, Lalive, P.-H., additional, Le Page, E., additional, Marque, P., additional, Michel, L., additional, Moisset, X., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pelé, F., additional, Pelletier, J., additional, Pittion-Vouyovitch, S., additional, Ramelli, A.-L., additional, Ruet, A., additional, Thouvenot, E., additional, Veillard, D., additional, Vignal-Clermont, C., additional, and Vukusic, S., additional

Published
2017
Full Text
View/download PDF

30. Diagnostic positif de la sclérose en plaques

Author

Brochet, Bruno, primary, Lebrun-Frénay, Christine, additional, de Sèze, Jérôme, additional, Zéphir, Hélène, additional, Allart, E., additional, Audoin, B., additional, Ayrignac, X., additional, Bensa, C., additional, Blanchard-Dauphin, A., additional, Brassat, D., additional, Carra-Dallière, C., additional, Clavelou, P., additional, Cohen, M., additional, Créange, A., additional, Collongues, N., additional, Debouverie, M., additional, Defer, G., additional, de Sèze, M., additional, Donzé, C., additional, Edan, G., additional, Fromont, A., additional, Gamé, X., additional, Gout, O., additional, Guillon, C., additional, Harand, C., additional, Jenny, B., additional, Labauge, P., additional, Lalive, P.-H., additional, Le Page, E., additional, Marque, P., additional, Michel, L., additional, Moisset, X., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pelé, F., additional, Pelletier, J., additional, Pittion-Vouyovitch, S., additional, Ramelli, A.-L., additional, Ruet, A., additional, Thouvenot, E., additional, Veillard, D., additional, Vignal-Clermont, C., additional, and Vukusic, S., additional

Published
2017
Full Text
View/download PDF

31. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Author

Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E.K., Debouverie M., Patti F., De Seze J., Izquierdo G., Eichau S., Edan G., Prat A., Girard M., Ozakbas S., Grammond P., Zephir H., Ciron J., Maillart E., Moreau T., Amato M.P., Labauge P., Alroughani R., Buzzard K., Skibina O., Terzi M., Laplaud D.A., Berger E., Grand'Maison F., Lebrun-Frenay C., Cartechini E., Boz C., Lechner-Scott J., Clavelou P., Stankoff B., Prevost J., Kappos L., Pelletier J., Shaygannejad V., Yamout B.I., Khoury S.J., Gerlach O., Spitaleri D.L.A., Van Pesch V., Gout O., Turkoglu R., Heinzlef O., Thouvenot E., McCombe P.A., Soysal A., Bourre B., Slee M., Castillo-Trivino T., Bakchine S., Ampapa R., Butler E.G., Wahab A., Macdonell R.A., Aguera-Morales E., Cabre P., Ben N.H., Van der Walt A., Laureys G., Van Hijfte L., Ramo-Tello C.M., Maubeuge N., Hodgkinson S., Sanchez-Menoyo J.L., Barnett M.H., Labeyrie C., Vucic S., Sidhom Y., Gouider R., Csepany T., Sotoca J., de Gans K., Al-Asmi A., Fragoso Y.D., Vukusic S., Butzkueven H., Kalincik T., Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E.K., Debouverie M., Patti F., De Seze J., Izquierdo G., Eichau S., Edan G., Prat A., Girard M., Ozakbas S., Grammond P., Zephir H., Ciron J., Maillart E., Moreau T., Amato M.P., Labauge P., Alroughani R., Buzzard K., Skibina O., Terzi M., Laplaud D.A., Berger E., Grand'Maison F., Lebrun-Frenay C., Cartechini E., Boz C., Lechner-Scott J., Clavelou P., Stankoff B., Prevost J., Kappos L., Pelletier J., Shaygannejad V., Yamout B.I., Khoury S.J., Gerlach O., Spitaleri D.L.A., Van Pesch V., Gout O., Turkoglu R., Heinzlef O., Thouvenot E., McCombe P.A., Soysal A., Bourre B., Slee M., Castillo-Trivino T., Bakchine S., Ampapa R., Butler E.G., Wahab A., Macdonell R.A., Aguera-Morales E., Cabre P., Ben N.H., Van der Walt A., Laureys G., Van Hijfte L., Ramo-Tello C.M., Maubeuge N., Hodgkinson S., Sanchez-Menoyo J.L., Barnett M.H., Labeyrie C., Vucic S., Sidhom Y., Gouider R., Csepany T., Sotoca J., de Gans K., Al-Asmi A., Fragoso Y.D., Vukusic S., Butzkueven H., and Kalincik T.

Abstract

OBJECTIVES: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. METHOD(S): This was a retrospective cohort study from two large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12-months were included in the analysis. The primary study outcome was annualised relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. RESULT(S): 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for seven therapies. Annualised rates of relapse (ARR) started to increase 2-months after natalizumab cessation (month 2-4 ARR, 95% confidence interval): 0.47, 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89), and stabilised faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01-0.29). Magnitude of disease reactivation for other therapies was low, but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were higher relapse rate in the year before cessation, female sex, younger age and higher EDSS. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95%CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). CONCLUSION(S): The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different t

Published
2022

32. Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Author

Simpson-Yap, S, Pirmani, A, Kalincik, T, De Brouwer, E, Geys, L, Parciak, T, Helme, A, Rijke, N, Hillert, JA, Moreau, Y, Edan, G, Sharmin, S, Spelman, T, McBurney, R, Schmidt, H, Bergmann, AB, Braune, S, Stahmann, A, Middleton, RM, Salter, A, Bebo, B, van der Walt, A, Butzkueven, H, Ozakbas, S, Boz, C, Karabudak, R, Alroughani, R, Rojas, J, van der Mei, IA, do Olival, GS, Magyari, M, Alonso, RN, Nicholas, RS, Chertcoff, AS, de Torres, AZ, Arrambide, G, Nag, N, Descamps, A, Costers, L, Dobson, R, Miller, A, Rodrigues, P, Prckovska, V, Comi, G, Peeters, LM, Simpson-Yap, S, Pirmani, A, Kalincik, T, De Brouwer, E, Geys, L, Parciak, T, Helme, A, Rijke, N, Hillert, JA, Moreau, Y, Edan, G, Sharmin, S, Spelman, T, McBurney, R, Schmidt, H, Bergmann, AB, Braune, S, Stahmann, A, Middleton, RM, Salter, A, Bebo, B, van der Walt, A, Butzkueven, H, Ozakbas, S, Boz, C, Karabudak, R, Alroughani, R, Rojas, J, van der Mei, IA, do Olival, GS, Magyari, M, Alonso, RN, Nicholas, RS, Chertcoff, AS, de Torres, AZ, Arrambide, G, Nag, N, Descamps, A, Costers, L, Dobson, R, Miller, A, Rodrigues, P, Prckovska, V, Comi, G, and Peeters, LM

Abstract

BACKGROUND AND OBJECTIVES: Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed. METHODS: Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab. RESULTS: Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1-7] and 7% [95% CI 4-11]), ICU/artificial ventilation (2% [95% CI 0-4] and 4% [95% CI 2-6]), and death (1% [95% CI 0-2] and 2% [95% CI 1-4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2-8), 3% (95% CI 1-5), and 1% (95% CI 0-3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19. DISCUSSION: Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 m

Published
2022

33. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Author

Lefort, M, Sharmin, S, Andersen, JB, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Seze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanche, JP, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Nifle, C, Laplaud, DA, Horakova, D, Dimitri-Boulos, D, Havrdova, EK, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, PS, Christensen, CCH, Rasmussen, P, Jensen, MB, Frederiksen, JL, Bramow, S, Mathiesen, HK, Schreiber, K, Butzkueven, H, Magyari, M, Kalincik, T, Leray, E, Lefort, M, Sharmin, S, Andersen, JB, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Seze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanche, JP, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Nifle, C, Laplaud, DA, Horakova, D, Dimitri-Boulos, D, Havrdova, EK, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, PS, Christensen, CCH, Rasmussen, P, Jensen, MB, Frederiksen, JL, Bramow, S, Mathiesen, HK, Schreiber, K, Butzkueven, H, Magyari, M, Kalincik, T, and Leray, E

Abstract

BACKGROUND: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. METHODS: Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. RESULTS: Overall, 5,148 relapsing-remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. CONCLUSIONS: This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is ful

Published
2022

34. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Author

Roos, I, Malpas, C, Leray, E, Casey, R, Horakova, D, Havrdova, EK, Debouverie, M, Patti, F, De Seze, J, Izquierdo, G, Eichau, S, Edan, G, Prat, A, Girard, M, Ozakbas, S, Grammond, P, Zephir, H, Ciron, J, Maillart, E, Moreau, T, Amato, MP, Labauge, P, Alroughani, R, Buzzard, K, Skibina, O, Terzi, M, Laplaud, DA, Berger, E, Grand'Maison, F, Lebrun-Frenay, C, Cartechini, E, Boz, C, Lechner-Scott, J, Clavelou, P, Stankoff, B, Prevost, J, Kappos, L, Pelletier, J, Shaygannejad, V, Yamout, B, Khoury, SJ, Gerlach, O, Spitaleri, DLA, Van Pesch, V, Gout, O, Turkoglu, R, Heinzlef, O, Thouvenot, E, McCombe, PA, Soysal, A, Bourre, B, Slee, M, Castillo-Trivino, T, Bakchine, S, Ampapa, R, Butler, EG, Wahab, A, Macdonell, RA, Aguera-Morales, E, Cabre, P, Ben, NH, Van der Walt, A, Laureys, G, Van Hijfte, L, Ramo-Tello, CM, Maubeuge, N, Hodgkinson, S, Sanchez-Menoyo, JL, Barnett, MH, Labeyrie, C, Vucic, S, Sidhom, Y, Gouider, R, Csepany, T, Sotoca, J, de Gans, K, Al-Asmi, A, Fragoso, YD, Vukusic, S, Butzkueven, H, Kalincik, T, Roos, I, Malpas, C, Leray, E, Casey, R, Horakova, D, Havrdova, EK, Debouverie, M, Patti, F, De Seze, J, Izquierdo, G, Eichau, S, Edan, G, Prat, A, Girard, M, Ozakbas, S, Grammond, P, Zephir, H, Ciron, J, Maillart, E, Moreau, T, Amato, MP, Labauge, P, Alroughani, R, Buzzard, K, Skibina, O, Terzi, M, Laplaud, DA, Berger, E, Grand'Maison, F, Lebrun-Frenay, C, Cartechini, E, Boz, C, Lechner-Scott, J, Clavelou, P, Stankoff, B, Prevost, J, Kappos, L, Pelletier, J, Shaygannejad, V, Yamout, B, Khoury, SJ, Gerlach, O, Spitaleri, DLA, Van Pesch, V, Gout, O, Turkoglu, R, Heinzlef, O, Thouvenot, E, McCombe, PA, Soysal, A, Bourre, B, Slee, M, Castillo-Trivino, T, Bakchine, S, Ampapa, R, Butler, EG, Wahab, A, Macdonell, RA, Aguera-Morales, E, Cabre, P, Ben, NH, Van der Walt, A, Laureys, G, Van Hijfte, L, Ramo-Tello, CM, Maubeuge, N, Hodgkinson, S, Sanchez-Menoyo, JL, Barnett, MH, Labeyrie, C, Vucic, S, Sidhom, Y, Gouider, R, Csepany, T, Sotoca, J, de Gans, K, Al-Asmi, A, Fragoso, YD, Vukusic, S, Butzkueven, H, and Kalincik, T

Abstract

BACKGROUND AND OBJECTIVES: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. METHODS: This was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. RESULTS: A total of 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for 7 therapies. Annualized rates of relapse (ARRs) started to increase 2 months after natalizumab cessation (month 2-4 ARR 0.47, 95% CI 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89) and stabilized faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01 to 0.29). The magnitude of disease reactivation for other therapies was low but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were a higher relapse rate in the year before cessation, female sex, younger age, and higher EDSS score. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95% CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). DISCUSSION: The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued di

Published
2022

35. Impact of methodological choices in comparative effectiveness studies:application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Author

Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand’Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T., Leray, E., Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand’Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T., and Leray, E.

Abstract

Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing–remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. Methods: Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. Results: Overall, 5,148 relapsing–remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. Conclusions: This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is

Published
2022

37. Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial

Author

Michel, M., primary, Le Page, E., additional, Laplaud, D.A., additional, Wardi, R., additional, Lebrun, C., additional, Zagnoli, F., additional, Wiertlewski, S., additional, Coustans, M., additional, Edan, G., additional, Chevreul, K., additional, Veillard, D., additional, Lallement, F., additional, Cohen, M., additional, Blanchard, C., additional, Sartori, E., additional, Demarco, O., additional, Rouhart, F., additional, Papeix, C., additional, Taurin, G., additional, Anani, T., additional, Kassiotis, P., additional, Hamon, C., additional, Lester, M.A., additional, and Merienne, M., additional

Published
2022
Full Text
View/download PDF

38. Deciphering multiple sclerosis disability progression in the elderly: a multicenter cohort study

Author

Ouallet, J-C, Rollot, F., Casey, R., Edan, G., Vukusic, S, Jonchère, Laurent, CHU Bordeaux [Bordeaux], CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Hospices Civils de Lyon (HCL)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

International audience

Published
2022

39. Treating active MS following induction therapies

Author

Edan, G., Le Page, E., Jonchère, Laurent, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

International audience; Meeting Abstract O04938th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-SclerosisAmsterdam, NETHERLANDSOCT 26-28, 2022

Published
2022

40. List of Contributors

Author

Aharoni, R., primary, Amato, M.P., additional, Andreasen, A.K., additional, Antel, J., additional, Arnon, R., additional, Avidan, N., additional, Avolio, C., additional, Bar-Or, A., additional, Baruch, K., additional, Berkovich, R., additional, Berneman, Z.N., additional, Ciceri, F., additional, Cohen, I.R., additional, Coles, A., additional, Comi, G., additional, Compston, A., additional, Cools, N., additional, Damoiseaux, J., additional, De Feo, D., additional, Deckx, N., additional, Edan, G., additional, Fadda, G., additional, Filippi, M., additional, Freedman, M.S., additional, Friedman, N., additional, Giatti, S., additional, Gold, R., additional, Gold, S.M., additional, Goretti, B., additional, Grazioli, E., additional, Gross, R.H., additional, Healy, L.M., additional, Hohlfeld, R., additional, Hupperts, R., additional, Jones, J., additional, Karussis, D., additional, Kassis, I., additional, Kieseier, B.C., additional, Kolb, C., additional, Lassmann, H., additional, Laterza, C., additional, Lejbkowicz, I., additional, Leussink, V.I., additional, Linker, R.A., additional, Lublin, F., additional, Martino, G., additional, McCauley, J.L., additional, Melcangi, R.C., additional, Merlini, A., additional, Michell-Robinson, M.A., additional, Miller, A., additional, Oksenberg, J.R., additional, Paperna, T., additional, Petrou, P., additional, Quintana, F.J., additional, Radaelli, M., additional, Rao, V.T.S., additional, Regev, K., additional, Rocca, M.A., additional, Salmen, A., additional, Schippling, S., additional, Schreiber, K., additional, Schwartz, M., additional, Smolders, J., additional, Sorensen, P.S., additional, Staun-Ram, E., additional, Steinman, L., additional, Touil, H., additional, Trojano, M., additional, Warnke, C., additional, Weiner, H.L., additional, Weinstock-Guttman, B., additional, Wekerle, H., additional, and Weller, R.O., additional

Published
2016
Full Text
View/download PDF

48. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

Author

Filippi, Massimo, Rocca, Maria A, Pagani, Elisabetta, De Stefano, Nicola, Jeffery, Douglas, Kappos, Ludwig, Montalban, Xavier, Boyko, Alexei N, Comi, Giancarlo, Filippi, M, Rocca, MA, Absinta, M, Longoni, G, Galantucci, S., Pagani, E, DallʼOcchio, L., Misci, P., Petrolini, M., Sala, S., Vuotto, R., Comi, G, Boyko, A, Filippi, M, Jeffery, D, Kappos, L, Montalban, x, McFarland, H, Bauer, K, Galay, N, Weber, J, Franta, C, Lampi, C, Shotekov, P, Bozhinov, S, Deleva, N, Haralanov, L, Ivanova Hristova, S, Petrov, I, Milanov, I, Kremenchutzky, M, Rabinovitch, H, Ayotte, C, GrandMaison, F, Lamontagne, A, Leckey, R, Lee, L, Hradilek, P, Kanovsky, P, Gross-Paju, K, Taba, P, Vermersch, P, Rumbach, L, Clavelou, P, Confavreux, C, Pelletier, J, Edan, G, Shakarishvili, R, Tsiskaridze, A, Becker, E, Chan, A, Eggers, J, Haas, J, Heesen, C, Heidenreich, F, Koehler, J., Koelmel, H W, Linker, R, Oschmann, P, Rauer, S, Maschke, M, Mueller, M, Reifschneider, G, Wildemann, B, Steinbrecher, A, Tumani, H, Ziebold, U, Ziemssen, T, Kanya, J, Jakab, G, Valikovics, A, Bartos, L, Karussis, D, Rawashdeh, H, Karni, A, Chapman, J, Comi, G, Caputo, D, Centonze, D, Cottone, S, Ghezzi, A, Maimone, D, Montanari, E, Plewnia, K, Scarpini, E, Metra, M, Rastenyte, D, Sceponaviciute, S, De Jong, B, Frequin, S, Visser, L, Zwanikken, C., Selmaj, K, Blaszczyk, B., Wajgt, A, Nowak, R, Jasinska, E, Brola, W, Sobkowiak-Osinska, M, Kapustecki, J, Zaborski, J, Panea, CA, Simu, M, Bulboaca, AC, Balasa, RI, Carciumaru, N, Boyko, A, Skoromets, A, Stolyarov, I, Perfilyev, S, Odinak, M, Amelina, O, Malkova, N, Gustov, A, Volkova, L, Shutov, A, Drulovic, J, Vojinovic, S, Montalban, Arroyo, R, Saiz Hinarejos, A, Brieva, L, Ramio, L, Meca Lallana, J, Amigo Jorrin, MdC, Prieto, JM, Munoz Gracia, D, Aladro, Y, Coret, F, Escartin, A, Diez Tejedor, E, Hillert, J, Olddon, T, Martin, C, Idiman, E, Sharrack, B, Giovannoni, G, Young, C, Nehrych, T, Moskovko, S, Kobys, T, AIpatov, Loganovskyi, K, AbouZeid, N, Jeffery, D, Dihenia, B, Carpenter, A, Flitman, S, Gazda, S, Goodman, A, Green, B, Gupta, A, Herbert, J, Hughes, B, Jacobs, A, Khatri, B, Lynch, S, Miller, T, Markowitz, C, Murray, R, Pardo, G, Parry, G, Gottschalk, G, Rossman, H, Scaberry, S, Thomas, F, Turel, A, Anderson, G, CTwyman, and Wyn, D

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results